Assiut University
Asyut, Egypt
NCT Number: NCT07114978
* To determine whether LVOT VTI < 15 cm predicts the development of in-hospital cardiogenic shock or need for vasopressors in STEMI patients undergoing primary PCI. * To assess association of LVOT VTI with other adverse outcomes (in-hospital death, heart failure, arrhythmias, need for mechanical ventilation, prolonged hospital stay).
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Asyut, Egypt
ST-elevation myocardial infarction (STEMI) remains a leading cause of cardiovascular mortality globally, with an estimated incidence of 50-100 cases per 100,000 person and accounting for nearly 30% of acute coronary syndrome (ACS) presentations. Despite advances in reperfusion therapy, in-hospital complications such as cardiogenic shock (CS) and acute heart failure (HF) continue to affect 5-15% of STEMI patients, with CS-associated mortality exceeding 40%.
Primary percutaneous coronary intervention (PCI) is the standard of care in STEMI patients, but also early identification of high-risk patients is crucial to improving outcomes.
Echocardiographic evaluation of left ventricular outflow tract velocity-time integral (LVOT VTI) has gained attention as a dynamic, bedside echocardiographic parameter that reflects stroke volume (SV) and cardiac output (CO). Several studies in critically ill patients and those with heart failure have shown that low LVOT VTI values (<15 cm) are associated with impaired cardiac output and adverse outcomes, including hypotension, vasopressor requirement, and increased mortality. Moreover, in cardiogenic shock, LVOT VTI has demonstrated superior prognostic accuracy compared to conventional measures such as left ventricular ejection fraction (LVEF).
Despite this growing evidence, the prognostic role of LVOT VTI in STEMI patients remains under-investigated. Since STEMI-related LV dysfunction directly impacts stroke volume, LVOT VTI may offer an early, non-invasive indicator of impending hemodynamic deterioration ـــ potentially before clinical signs become evident. Early identification of those high-risk patients mandates careful hemodynamic monitoring and rapid management of any deterioration.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
simple, bedsided, non-invasive
Time frame: Through hospital stay (up to 3 days)
Cardiogenic shock defined per ESC 2023 criteria (SBP <90 mmHg for ≥30 minutes plus signs of hypoperfusion, or need for vasopressors/inotropic support). Assessed during hospital stay in relation to baseline LVOT VTI.
Unit of Measure: Percentage of patients (%)
Time frame: Through hospital stay (up to 3 days)
Defined by signs/symptoms requiring intravenous diuretics or ventilatory support, assessed during hospital stay.
Unit of Measure: Percentage of patients (%)
Time frame: Through hospital stay (up to 3 days)
Occurrence of sustained VT or VF requiring intervention, assessed through hospital stay.
Unit of Measure: Percentage of patients (%)
Time frame: Through hospital stay (up to 3 days)
Use of invasive or non-invasive mechanical ventilatory support during hospital stay.
Unit of Measure: Percentage of patients (%)
Time frame: Through study completion (an average 1 year )
Number of days from admission to discharge. Unit of Measure: Days
Contact information is provided by the study sponsor or research team.
Ahmed Khaled Ahmed Abdel Rahman, Resident doctor
CONTACT
Mohammad Aboelkasem Ali Mousa, Lecturer
CONTACT
Assiut University
Other
Prognostic Value of the Left Ventricular Outflow Tract Velocity-time Integral in Predicting In-hospital Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07175259
Cardiovascular Diseases, Heart Diseases
View Trial DetailsNCT06876974
Cardiovascular Diseases, Heart Diseases
View Trial DetailsNCT05510661
Cardiovascular Diseases, Heart Diseases
Karachi, Sindh, Pakistan
View Trial DetailsNCT06678074
Cardiovascular Diseases, Heart Diseases
St Louis, Missouri, United States
View Trial Details